- In vivo studies using phage therapy against MDR bacteria.
| Organism | Model | Bacteriophage | Outcome | Reference |
|---|---|---|---|---|
| Carbapenem resistant A. baumannii | Galleria mellonella larva | 2 lytic phages (WCHABP1 and WCHABP12) | Either phage WCHABP1 or WCHABP12 protected the larvae from a leathal dose of A. baumannii | (24) |
| MDR A. baumannii | Galleria mellonella larva Murine skin and murine lung infection models | Endolysin ElyA1 and colistin | The combination of ElyA1 and colistin increased survival rate of the treated larvae The combination of ElyA1 and colistin decreased bacterial load in the skin wounds of the treated mice The combination of ElyA1 and colistin reduced bacterial load in the lungs of the treated mice | (34) |
| MRSA and VISA | Mice | AB-SA01 | Resulted in a substantial decrease in bacterial burden within the lungs of mice subjected to treatment | (36) |
| MRSA | Mouse model of lung-derived septicemia | S130’ | Led to a significant increased in survival rate of treated mice | (29) |
| MRSA | Nude mice | Phage JD007 | Prevented S. aureus from dermal abscesses formation Phage JD007 did not cause a robust immune responses in treated mice | (30) |
| Carbapenem-resistant A. baumannii | Mice | Phage SH-Ab15519 | Enhanced the survival rate among the mice that received treatment | (37) |
| XDR A. baumannii | Mice | ϕkm18p | Enhanced the survival rate among the mice that received treatment and decreased bacterial load within them | (25) |
| MDR K. pneumoniae | Mice | 1513 | Resulted in a higher survival rate among the mice that received treatment | (38) |
A. baumannii: Acinetobacter baumannii, MDR: Multidrug-resistant, MRSA: Methicillin-resistant Staphylococcus aureus, VISA: Vancomycin-intermediate Staphylococcus aureus, K. pneumoniae: Klebsiella pneumoniae, XDR: extensively drug resistant, S. aureus: Staphylococcus aureus